BR112018012844A2 - polipeptídeos para inibir a ativação de complemento - Google Patents

polipeptídeos para inibir a ativação de complemento

Info

Publication number
BR112018012844A2
BR112018012844A2 BR112018012844A BR112018012844A BR112018012844A2 BR 112018012844 A2 BR112018012844 A2 BR 112018012844A2 BR 112018012844 A BR112018012844 A BR 112018012844A BR 112018012844 A BR112018012844 A BR 112018012844A BR 112018012844 A2 BR112018012844 A2 BR 112018012844A2
Authority
BR
Brazil
Prior art keywords
polypeptides
complement activation
inhibit complement
effector domain
convertase
Prior art date
Application number
BR112018012844A
Other languages
English (en)
Inventor
HÄFFNER Karsten
Michelfelder Stefan
Original Assignee
Greenovation Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenovation Biotech Gmbh filed Critical Greenovation Biotech Gmbh
Publication of BR112018012844A2 publication Critical patent/BR112018012844A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a um polipeptídeo compreendendo um domínio efetor da c3 convertase, um domínio efetor da c5 convertase e opcionalmente um domínio efetor inibidor do complexo terminal que é resistente à desregulação por proteínas fhr fisiológicas e tem um motivo de dimerização, e ao seu uso terapêutico.
BR112018012844A 2015-12-23 2016-12-23 polipeptídeos para inibir a ativação de complemento BR112018012844A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015016665 2015-12-23
PCT/EP2016/082614 WO2017109208A1 (en) 2015-12-23 2016-12-23 Polypeptides for inhibiting complement activation

Publications (1)

Publication Number Publication Date
BR112018012844A2 true BR112018012844A2 (pt) 2018-12-04

Family

ID=57838331

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012844A BR112018012844A2 (pt) 2015-12-23 2016-12-23 polipeptídeos para inibir a ativação de complemento

Country Status (19)

Country Link
US (2) US10640540B2 (pt)
EP (1) EP3394089B1 (pt)
JP (2) JP6771568B2 (pt)
KR (1) KR20180091097A (pt)
CN (1) CN108699121B (pt)
AU (1) AU2016375183B2 (pt)
BR (1) BR112018012844A2 (pt)
CA (1) CA3009393C (pt)
DK (1) DK3394089T3 (pt)
ES (1) ES2895256T3 (pt)
HR (1) HRP20211608T1 (pt)
HU (1) HUE056019T2 (pt)
IL (1) IL260182B2 (pt)
LT (1) LT3394089T (pt)
MX (1) MX2018007392A (pt)
PL (1) PL3394089T3 (pt)
PT (1) PT3394089T (pt)
SI (1) SI3394089T1 (pt)
WO (1) WO2017109208A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117338781A (zh) * 2017-08-31 2024-01-05 诺华股份有限公司 哌啶基-吲哚衍生物的用途
US20200262879A1 (en) 2017-09-11 2020-08-20 Insideoutbio, Inc. Methods and compositions to enhance the immunogenicity of tumors
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
DE102018120016B4 (de) * 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097440B1 (en) * 1982-06-14 1986-09-24 The Upjohn Company Method and kit for removing and assaying complement system fragments
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ZA200807620B (en) * 2006-03-08 2009-12-30 Archemix Corp Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
NZ614351A (en) 2008-11-10 2015-05-29 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders
JP5740772B2 (ja) * 2009-08-31 2015-07-01 アイビーシー ファーマスーティカルズ，インコーポレイテッド 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用
WO2011156356A1 (en) * 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
NZ709997A (en) 2011-04-08 2016-03-31 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
CN102978204B (zh) * 2011-11-11 2018-06-08 张康 Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法
WO2013142362A1 (en) * 2012-03-19 2013-09-26 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
FR3015484A1 (fr) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
WO2020232319A1 (en) * 2019-05-15 2020-11-19 Insideoutbio, Inc. Modular therapeutics for the treatment of inflammatory diseases and cancer
WO2021247487A1 (en) * 2020-06-01 2021-12-09 Medical University Of South Carolina Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders

Also Published As

Publication number Publication date
US20190300589A1 (en) 2019-10-03
IL260182B2 (en) 2023-12-01
JP2020167999A (ja) 2020-10-15
US20200277347A1 (en) 2020-09-03
CA3009393C (en) 2023-08-22
ES2895256T3 (es) 2022-02-18
AU2016375183A1 (en) 2018-07-19
JP2019508022A (ja) 2019-03-28
KR20180091097A (ko) 2018-08-14
DK3394089T3 (da) 2021-11-01
HRP20211608T1 (hr) 2022-01-21
LT3394089T (lt) 2021-11-25
US10640540B2 (en) 2020-05-05
IL260182A (en) 2018-07-31
MX2018007392A (es) 2018-08-15
WO2017109208A1 (en) 2017-06-29
PT3394089T (pt) 2021-11-03
CA3009393A1 (en) 2017-06-29
EP3394089A1 (en) 2018-10-31
SI3394089T1 (sl) 2021-12-31
EP3394089B1 (en) 2021-07-28
AU2016375183B2 (en) 2021-01-21
CN108699121B (zh) 2023-07-04
CN108699121A (zh) 2018-10-23
US11591378B2 (en) 2023-02-28
HUE056019T2 (hu) 2022-01-28
PL3394089T3 (pl) 2022-01-17
JP6771568B2 (ja) 2020-10-21
IL260182B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112018012844A2 (pt) polipeptídeos para inibir a ativação de complemento
MX2020013881A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
EP3123954C0 (en) SURGICAL INSTRUMENT WITH SYSTEMS TO ENSURE CORRECT SEQUENTIAL OPERATION OF THE SURGICAL INSTRUMENT
DK3308793T3 (da) Terapeutisk middel til hudsår eller ru hud
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
GT201600249A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
EP3402417A4 (en) ENDOSCOPIC RESTABLE SURGICAL STAPLER APPLICATOR
BR112017004209A2 (pt) derivados de tetrahidronaftaleno que inibem a proteína mcl-1.
BR112019007613A2 (pt) terapia de combinação para inibição de c3
GB201902811D0 (en) Token-based electrosurgical instrument activation
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
BR112018002550A2 (pt) mecanismo de resistência a inibidores do bromodomínio de bet
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112017000428A2 (pt) produtos imunogênicos com base em sequências de amino ácidos muteína b (ab) amiloide e uso dos mesmos
BR112016029808A2 (pt) ?suporte para filtro?
ZA201901488B (en) Ni-containing catalyst for the oligomerization of olefins
BR112018001852A2 (pt) instrumento cirúrgico compreendendo sistemas para garantir a operação sequencial adequada do instrumento cirúrgico
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CO2017011295A2 (es) Piroglutamato de vortioxetina
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
BR112018076553A2 (pt) composição de dois componentes.
EP3708161A4 (en) MITOCHONDRIAL DYSFUNCTION IMPROVEMENT AGENTS, PROPHYLACTIC OR THERAPEUTIC FOR DISEASES OR SYMPTOMS CAUSED BY MITOCHONDRIAL DYSFUNCTION AND USES THEREFORE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ELEVA GMBH (DE)